Amgen Announces Top-Line Data From Remicade Biosimilar Study
Amgen (AMGN) presents top-line results from a late-stage study evaluating its biosimilar version of Remicade. Data shows that there was no clinically meaningful difference between the two products.
Source:: https://finance.yahoo.com/news/amgen-announces-top-line-data-123012969.html
